Expert review of cardiovascular therapy · 2025
Direct oral anticoagulants versus vitamin K antagonists in concurrent hypertrophic cardiomyopathy and atrial fibrillation: a meta-analysis.
СтатьяМетаанализСистематический обзорСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aboutorabi Max, Ahmad Mahmood, Flora Kiran, Ferreira Hugo, Chiu Michael, Bray Jonathan J H, Kumar Niraj S, Providencia Rui
Аннотация
INTRODUCTION: Twenty to twenty-five percent of patients with hypertrophic cardiomyopathy (HCM) have concurrent atrial fibrillation (AF). It is unclear whether direct oral anticoagulants (DOAC) are a safe and effective alternative to vitamin K antagonists (VKA) in concurrent HCM and AF.
METHODS: We performed a systematic review and meta-analysis of original reports comparing DOACs versus VKAs in concurrent HCM and AF. The protocol was published in PROSPERO -CRD42024575553. MEDLINE, Embase, and Cochrane Central were searched from inception to October 2024.
RESULTS: From 1119 records retrieved by the search, we identified 8 different observational studies (n = 14,243). Compared to VKAs, DOACs were associated with a lower rate of thromboembolic events 318/8322 vs. 559/5921 (OR 0.44, 95% CI 0.23-0.83; p = 0.0118; I2 = 84%; NNT = 18), and less major bleeds 289/8322 vs. 327/5921 (OR 0.54, 95% CI 0.36-0.80; p = 0.0021; I2 = 76%; NNT = 49). Apixaban and dabigatran were associated with lower rate of thromboembolic events, major bleeding, all-cause death, and intracranial hemorrhage, and Rivaroxaban associated with less all-cause deaths and intracranial hemorrhages, compared to VKAs (all p < 0.05).
CONCLUSIONS: DOACs demonstrated good efficacy and a favorable safety profile in patients with HCM and AF compared to VKAs.Registration: The protocol for this meta-analysis was published in PROSPERO (CRD420245755530).
METHODS: We performed a systematic review and meta-analysis of original reports comparing DOACs versus VKAs in concurrent HCM and AF. The protocol was published in PROSPERO -CRD42024575553. MEDLINE, Embase, and Cochrane Central were searched from inception to October 2024.
RESULTS: From 1119 records retrieved by the search, we identified 8 different observational studies (n = 14,243). Compared to VKAs, DOACs were associated with a lower rate of thromboembolic events 318/8322 vs. 559/5921 (OR 0.44, 95% CI 0.23-0.83; p = 0.0118; I2 = 84%; NNT = 18), and less major bleeds 289/8322 vs. 327/5921 (OR 0.54, 95% CI 0.36-0.80; p = 0.0021; I2 = 76%; NNT = 49). Apixaban and dabigatran were associated with lower rate of thromboembolic events, major bleeding, all-cause death, and intracranial hemorrhage, and Rivaroxaban associated with less all-cause deaths and intracranial hemorrhages, compared to VKAs (all p < 0.05).
CONCLUSIONS: DOACs demonstrated good efficacy and a favorable safety profile in patients with HCM and AF compared to VKAs.Registration: The protocol for this meta-analysis was published in PROSPERO (CRD420245755530).